Victory Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-45,064
| Closed | -$1.79M | – | 2556 |
|
|
2024
Q1 | $1.79M | Buy |
+45,064
| New | +$1.33M | ﹤0.01% | 1490 |
|
|
2020
Q2 | – | Sell |
-1,546
| Closed | -$4K | – | 3410 |
|
|
2020
Q1 | $4K | Buy |
+1,546
| New | +$4.81K | ﹤0.01% | 3374 |
|
|
2019
Q4 | – | Sell |
-132,603
| Closed | -$520K | – | 3398 |
|
|
2019
Q3 | $520K | Buy |
132,603
+1,581
| +1% | +$6.79K | ﹤0.01% | 1869 |
|
|
2019
Q2 | $552K | Sell |
131,022
-3,520
| -3% | -$20.3K | ﹤0.01% | 1363 |
|
|
2019
Q1 | $923K | Sell |
134,542
-1,530
| -1% | -$9.54K | ﹤0.01% | 1261 |
|
|
2018
Q4 | $501K | Buy |
136,072
+70,980
| +109% | +$350K | ﹤0.01% | 1364 |
|
|
2018
Q3 | $412K | Sell |
65,092
-3,430
| -5% | -$24K | ﹤0.01% | 1474 |
|
|
2018
Q2 | $519K | Sell |
68,522
-3,780
| -5% | -$31.1K | ﹤0.01% | 1358 |
|
|
2018
Q1 | $578K | Buy |
72,302
+20,751
| +40% | +$205K | ﹤0.01% | 1331 |
|
|
2017
Q4 | $577K | Buy |
51,551
+11,799
| +30% | +$128K | ﹤0.01% | 1308 |
|
|
2017
Q3 | $461K | Buy |
39,752
+18,678
| +89% | +$175K | ﹤0.01% | 1334 |
|
|
2017
Q2 | $203K | Buy |
+21,074
| New | +$202K | ﹤0.01% | 1441 |
|
Victory Capital Management's ALPN Position: Q2 2024 in Review
Victory Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 45,064 shares — an estimated $1.79M sold.
Victory Capital Management first reported a position in ALPN in Q2 2017 and held it in 12 quarters. The position peaked at $1.79M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Victory Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Victory Capital Management sold 45,064 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $1.79M.
- Victory Capital Management first reported a position in Alpine Immune Sciences Inc in Q2 2017 and held it in 12 quarters.
- Victory Capital Management's Alpine Immune Sciences Inc position peaked at $1.79M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Victory Capital Management's 13F filing for Q2 2024, filed 5 Aug 2024.